--- title: "US Treasury plans rules for China pharma deals" publication: "MediaBias News" url: "https://mediabias.news/politics/us-treasury-plans-rules-for-china-pharma-deals" api: "https://mediabias.news/api/v1/stories/us-treasury-plans-rules-for-china-pharma-deals" markdown: "https://mediabias.news/politics/us-treasury-plans-rules-for-china-pharma-deals.md" audio: "https://mediabias.news/api/audio/us-treasury-plans-rules-for-china-pharma-deals" category: "Politics" area: "United States" published: "2026-09-18T21:05:12.307Z" source_reported: "2026-09-18T18:40:01.000Z" updated: "2026-09-18T21:05:12.307Z" trust_score: 50 critic_score: 45 hype_score: 20 assessment_type: "coverage-and-source-reporting-analysis" fact_check_status: "not-performed" coverage_measured: "2026-09-18T21:00:46.436682+00:00" --- # US Treasury plans rules for China pharma deals *New regulations would likely permit most licensing agreements, with exceptions for sensitive biotechnology.* **Scores for the source reporting** (0-100, assessing the original journalism this article was written from, not this write-up): - Trust 50 of 100, higher is better. Central claim attributed to named body (Reuters) and three sources, but no documents or independent outlets. - Craft 45 of 100, higher is better. Reporting is clear and holds together, but lacks quotes from affected parties or discussion of future implications. - Hype 20 of 100, lower is better. The language used is measured and proportionate, with no sensationalism or manufactured urgency. Scored by MediaBias News; method at https://mediabias.news/methodology. **The short version** - The U.S. Treasury Department is formulating rules for biopharma companies investing in China. - The proposed rules would likely permit most licensing deals for drugs originating in China. - Exceptions may apply to deals involving weaponizable biotechnology or pathogens. - Some U.S. pharmaceutical leaders favour fewer restrictions, while others urge caution. The U.S. Treasury Department is formulating rules that would govern biopharmaceutical companies investing in China. These regulations are expected to allow the majority of licensing deals for drugs that originate in China. The rules may include exceptions for deals involving weaponizable biotechnology or pathogens, according to three sources familiar with the matter who spoke to Reuters. ## Divergent views on China investment Within the U.S. pharmaceutical industry, there are differing opinions on the extent of restrictions that should be placed on investments and collaborations with China. Leaders such as the CEO of Pfizer have expressed opposition to broad restrictions, stating they foresee no security threat in most collaborations. Conversely, some executives from smaller biotechnology firms have voiced concerns about strategic reliance on China and are advocating for increased caution. ## What the coverage left out None of the centre- or right-rated reports mention the specific reasons why U.S. and European drugmakers are increasingly collaborating with Chinese biopharma companies, such as seeking access to innovative medicines to replenish pipelines ahead of patent expirations on major drugs, as reported by Reuters in its full report. ## Who covered it Shares of the 6 covering outlets with a published leaning rating: - Left: 0% (0) - Centre: 50% (3) - Right: 50% (3) 5 of 11 covering outlets carried no usable leaning rating and were excluded from those percentages. Coverage measured 2026-09-18T21:00:46.436682+00:00. **Coverage watch:** developing. Checked 2 times; 0 checks found a material change. Most recently checked 2026-09-18T21:30:47.920Z. ## How the sides framed it ### Left No separate framing summary. ### Centre - Centre-rated reports led on the U.S. Treasury Department's formulation of rules for biopharma companies investing in China. These reports noted that the rules would likely preserve the ability to complete most licensing deals for drugs originating in the country. They also mentioned potential exceptions for weaponizable biotechnology or pathogens. The reports carried information from Reuters, citing three sources briefed on the process. ### Right - Right-rated reports focused on the U.S. weighing the allowance of most pharmaceutical licensing deals with China, citing sources. These reports indicated that the U.S. is working on rules for pharmaceutical companies investing in China that would likely preserve their ability to strike most licensing deals for Chinese drugs. They noted this would represent a departure from previous policies of hardening trade relations with China in other sectors. The reports also included commentary from Pfizer's CEO opposing broad restrictions and smaller biotech executives urging caution. **Provisional coverage gap:** left. The watch is not closed, so this is not yet a settled blindspot finding. ## Factuality profile of the covering outlets These are published factuality ratings of the outlets, not a verdict on whether this story or its claims are true. - high: 3 - unknown: 5 - veryHigh: 3 ## Verification scope This page compares coverage and scores the source reporting. It is not a ClaimReview verdict on whether the underlying event or claim is true. ## Original reporting this was written from - [Cryptocurrency News | Cryptocurrency Prices | Market Cap](https://cryptocurrency.com.tr/us-treasury-department-drafts-rules-to-keep-most-pharma-licensing-deals-with-china-alive-382726) — US Treasury Department drafts rules to keep most pharma licensing deals with China alive - [Crypto Briefing](https://cryptobriefing.com/us-treasury-pharma-licensing-rules-china) — US Treasury Department drafts rules to keep most pharma licensing deals with China alive - [OODA Loop](https://oodaloop.com/briefs/technology/us-weighs-allowing-most-pharma-licensing-deals-with-china) — US weighs allowing most pharma licensing deals with China - [Formiche.net](https://formiche.net/2026/09/farmaceutica-usa-cina-licensing-biotech) — Chinese Biotech, Towards New Rules for US Companies? Indiscretions - [STAT](https://statnews.com/pharmalot/2026/09/18/rules-for-china-licensing-deals-making-drugs-in-space) — Pharmalittle: We're reading about licensing deals with China, making drugs in space, and more - [iatronet.gr](https://iatronet.gr/article/142917/hpa-exetazetai-epektash-symfonion-adeiodothshs-farmakeytikon-proionton-apo-thn-kina) — US: Expanding Pharmaceutical Licensing Agreements with China Under Consideration - [regionalmedianews.com](https://regionalmedianews.com/news/national/health/exclusive-us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say) — Exclusive-US weighs allowing most pharma licensing deals with China, sources say - Regional Media News - [Globo](https://valor.globo.com/empresas/noticia/2026/09/18/eua-avaliam-permitir-maioria-dos-acordos-de-licenciamento-farmacutico-com-a-china-dizem-fontes.ghtml) — U.S. Estimates Allow Most Pharmaceutical Licensing Agreements with China, Sources Say - [Seeking Alpha](https://seekingalpha.com/news/4644250-usweighs-allowing-most-pharma-licensing-deals-china) — U.S. weighs allowing most pharma licensing deals with China - [WTVB](https://wtvbam.com/2026/09/18/exclusive-us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say) — Exclusive-US weighs allowing most pharma licensing deals with China, sources say - [Reuters](https://reuters.com/world/us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say-2026-09-18) — EXCLUSIVE: US weighs allowing most pharma licensing deals with China, sources say ## Questions **What are the proposed U.S. rules for biopharma companies investing in China?** The U.S. Treasury Department is formulating rules that are expected to allow most licensing deals for drugs originating in China. However, exceptions may be made for deals involving weaponizable biotechnology or pathogens, according to sources familiar with the matter. **What are the differing views among U.S. pharma leaders regarding China investments?** Some leaders, like Pfizer's CEO, oppose broad restrictions and see no security threat in collaborations. Others, particularly from smaller biotech firms, express concern about strategic reliance on China and advocate for caution. **Which types of deals might be restricted under the new U.S. rules?** The proposed rules are expected to allow most licensing deals for drugs originating in China. Potential restrictions could apply to agreements involving weaponizable biotechnology or pathogens, reflecting national security concerns. --- MediaBias News — https://mediabias.news. Reproduced from https://mediabias.news/politics/us-treasury-plans-rules-for-china-pharma-deals. Please cite as: MediaBias News, "US Treasury plans rules for China pharma deals", https://mediabias.news/politics/us-treasury-plans-rules-for-china-pharma-deals